Evidence map›Paper›PMID 40685627›Full record

ArticleBioinformatics (Oxford, England)2025

CoxKAN: Kolmogorov-Arnold networks for interpretable, high-performance survival analysis.

William Knottenbelt, William McGough, Rebecca Wray, Woody Zhidong Zhang, Jiashuai Liu, Ines Prata Machado, Zeyu Gao, Mireia Crispin-Ortuzar

Abstract read
In one paragraph

Article in Bioinformatics (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

William KnottenbeltDepartment of Oncology, University of Cambridge, Cambridge, CB2 0XZ, United Kingdom.
William McGoughDepartment of Oncology, University of Cambridge, Cambridge, CB2 0XZ, United Kingdom.
Rebecca WrayDepartment of Oncology, University of Cambridge, Cambridge, CB2 0XZ, United Kingdom.
Woody Zhidong ZhangDepartment of Oncology, University of Cambridge, Cambridge, CB2 0XZ, United Kingdom.
Jiashuai LiuSchool of Computer Science, Xi'an Jiaotong University, Xi'an, 710049, China.
Ines Prata MachadoDepartment of Oncology, University of Cambridge, Cambridge, CB2 0XZ, United Kingdom.
Zeyu GaoDepartment of Oncology, University of Cambridge, Cambridge, CB2 0XZ, United Kingdom.ORCID 0000-0003-2365-8318
Mireia Crispin-OrtuzarDepartment of Oncology, University of Cambridge, Cambridge, CB2 0XZ, United Kingdom.

Funding

Mark Foundation for Cancer Research RG95043
6 · The paper itself

Abstract

motivationSurvival analysis is a branch of statistics that is crucial in medicine for modeling the time to critical events such as death or relapse, in order to improve treatment strategies and patient outcomes. Selecting survival models often involves a trade-off between performance and interpretability; deep learning models offer high performance but lack the transparency of more traditional approaches. This poses a significant issue in medicine, where practitioners are reluctant to use black-box models for critical patient decisions.

resultsWe introduce CoxKAN, a Cox proportional hazards Kolmogorov-Arnold Network for interpretable, high-performance survival analysis. Kolmogorov-Arnold Networks (KANs) were recently proposed as an interpretable and accurate alternative to multi-layer perceptrons. We evaluated CoxKAN on four synthetic and nine real datasets, including five cohorts with clinical data and four with genomics biomarkers. In synthetic experiments, CoxKAN accurately recovered interpretable hazard function formulae and excelled in automatic feature selection. Evaluations on real datasets showed that CoxKAN consistently outperformed the traditional Cox proportional hazards model (by up to 4% in C-index) and matched or surpassed the performance of deep learning-based models. Importantly, CoxKAN revealed complex interactions between predictor variables and uncovered symbolic formulae, which are key capabilities that other survival analysis methods lack, to provide clear insights into the impact of key biomarkers on patient risk. AVAILABILITY AND IMPLEMENTATION: CoxKAN is available at GitHub and Zenodo.

Indexed as

Survival AnalysisAlgorithmsDeep LearningHumansProportional Hazards Models

Identifiers

PMID40685627
PMCPMC12341683

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.